Compare REPL & NUTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | NUTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | 944 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2018 | 2009 |
| Metric | REPL | NUTX |
|---|---|---|
| Price | $12.37 | $220.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $5.67 | ★ $252.50 |
| AVG Volume (30 Days) | ★ 1.8M | 116.6K |
| Earning Date | 05-21-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.93 |
| EPS | N/A | ★ 15.87 |
| Revenue | N/A | ★ $875,257,000.00 |
| Revenue This Year | N/A | $6.12 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | ★ N/A | $12.89 |
| Revenue Growth | N/A | ★ 82.36 |
| 52 Week Low | $1.50 | $83.99 |
| 52 Week High | $16.33 | $224.28 |
| Indicator | REPL | NUTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 63.76 |
| Support Level | $12.40 | $142.71 |
| Resistance Level | $16.02 | $224.28 |
| Average True Range (ATR) | 0.73 | 11.45 |
| MACD | -0.22 | -0.37 |
| Stochastic Oscillator | 16.61 | 87.54 |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.